Trial Profile
A Phase I, Open-Label, Randomized, Four-Treatment Period, Four-Sequence, Single-Dose, Crossover, Pharmacokinetic Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Pirfenidone (Primary) ; Pirfenidone (Primary)
- Indications Acute lung injury; Idiopathic pulmonary fibrosis
- Focus Pharmacokinetics
- Sponsors Roche
- 14 Aug 2017 Primary endpoint (AUC from Time Zero to Infinity (AUC[0-inf]) of Pirfenidone, in fed and fasted state, 1 801-mg tablet vs 3 267-mg capsules) has been met as per the results published in the Advances in Therapy
- 14 Aug 2017 Primary endpoint (Area Under the Plasma Concentration Versus Time Curve (AUC) from Time Zero to the Time of the Last Quantifiable Concentration (AUC[0-t]) of Pirfenidone, in fed and fasted state, 1 801-mg tablet vs 3 267-mg capsules) has been met as per the results published in the Advances in Therapy
- 14 Aug 2017 Primary endpoint (Peak Plasma Concentration (Cmax) of Pirfenidone, in fed state, 1 801-mg tablet vs 3 267-mg capsules) has not been met as per the results published in the Advances in Therapy